Portola Pharmaceuticals, Inc. — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4afb04e6-007c-4641-8e74-54499bd21fa6/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2019 | $-290.7M | 2019-01-01 – 2019-12-31 | evidence 0001628280-20-002568 |
| FY 2018 | $-350.2M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005772 |
| FY 2017 | $-286.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004153 |
| FY 2016 | $-269.0M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003123 |
| FY 2015 | $-226.5M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013714 |
| FY 2014 | $-137.1M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001190 |
| FY 2013 | $-83.4M | 2013-01-01 – 2013-12-31 | evidence 0001564590-14-000472 |
| FY 2012 | $11.4M | 2012-01-01 – 2012-12-31 | evidence 0001564590-14-000472 |
| FY 2011 | $20.0M | 2011-01-01 – 2011-12-31 | evidence 0001564590-14-000472 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Portola Pharmaceuticals, Inc. — all facts · Revenue · Operating Income